Drug Profile
Human papillomavirus vaccine recombinant pentavalent - Merck
Alternative Names: 5-valent HPV L1 VLP vaccine - Merck; Human papillomavirus (types 31, 33, 45, 52, 58) L1 virus-like particle vaccine - Merck; Pentavalent HPV VLP vaccine - Merck; Prophylactic 5-valent HPV (Types 31, 33, 45, 52, 58) L1 virus-like particle vaccine - Merck; V-504Latest Information Update: 25 Feb 2014
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cervical cancer; Human papillomavirus infections
Most Recent Events
- 01 Oct 2007 Phase-II clinical trials in Cervical cancer (prevention) in USA, Sweden and Austria (IM)
- 01 Oct 2007 Phase-II clinical trials in Human papillomavirus infections (prevention) in USA, Sweden and Austria (IM)